Ironwood Pharmaceuticals, Inc.
IRWD
$1.49
$0.042.76%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -19.47% | -12.09% | -28.05% | 9.66% | 4.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.47% | -12.09% | -28.05% | 9.66% | 4.70% |
| Cost of Revenue | -9.02% | 53.65% | 100.94% | 276.95% | 183.98% |
| Gross Profit | -23.70% | -26.94% | -46.21% | -19.20% | -16.62% |
| SG&A Expenses | 11.65% | 15.77% | 20.85% | 65.44% | 13.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.24% | 30.36% | 44.25% | 122.33% | 62.16% |
| Operating Income | -47.23% | -51.01% | -80.94% | -54.35% | -29.01% |
| Income Before Tax | -45.61% | 101.75% | -92.47% | -57.99% | -54.32% |
| Income Tax Expenses | -23.68% | 48.88% | -54.73% | 37.21% | -8.21% |
| Earnings from Continuing Operations | -73.86% | 99.92% | -109.10% | -103.57% | -72.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.20% | 99.92% | -109.10% | -102.22% | -69.55% |
| EBIT | -47.23% | -51.01% | -80.94% | -54.35% | -29.01% |
| EBITDA | -45.92% | -51.06% | -80.18% | -53.83% | -28.65% |
| EPS Basic | -76.81% | 99.92% | -108.92% | -102.20% | -70.09% |
| Normalized Basic EPS | -60.28% | -80.43% | -91.97% | -65.95% | -40.01% |
| EPS Diluted | -77.27% | 99.92% | -111.96% | -103.00% | -68.44% |
| Normalized Diluted EPS | -52.52% | -80.43% | -90.29% | -58.88% | -39.72% |
| Average Basic Shares Outstanding | 2.45% | 2.35% | 2.10% | 1.75% | 1.84% |
| Average Diluted Shares Outstanding | -14.26% | 2.35% | -15.52% | -15.75% | 1.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
